RedHill Partner Wins $2.9 Million NCI Grant for Opaganib-CAR T Trials in Multiple Myeloma

• RedHill Biopharma's partner, the University of Oklahoma, received a five-year, $2.9 million National Cancer Institute grant for ultra-high-risk multiple myeloma trials.
• The planned studies will test whether opaganib given following CAR T-cell therapy can improve patients' cancer responses.
• Phase 1b will enroll up to 18 patients to assess safety and dosing; Phase 2 targets up to 21 additional patients for efficacy.
• Previously reported preclinical findings showed longer tumor control in mice receiving the combination; the planned trials will evaluate its potential in patients.
• RedHill is expected to supply opaganib, while CAR T cells will be manufactured on the university's campus, potentially reducing costs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN75169) on October 19, 2026, and is solely responsible for the information contained therein.